I'm LongbridgeAI, I can summarize articles.Health care stocks rose as investors rotated into sectors less sensitive to fuel prices and interest rates. Novo Nordisk plans to rebrand as 'Novo' to better resonate with consumers against rival Eli Lilly. Meanwhile, AstraZeneca's new breast-cancer pill failed to meet its primary clinical trial goal of slowing disease progression, yet its shares still gained.
Health-care companies rose as traders rotated into sectors less susceptible to rising fuel prices and interest rates.
Wegovy maker Novo Nordisk plans to rebrand itself as Novo, betting a shorter name will help it resonate more with consumers as it competes with rival Eli Lilly.
AstraZeneca said its new breast-cancer pill missed the key goal of slowing the disease from worsening in a late-stage clinical trial. Shares of the British drug maker still gained.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
September 14, 2026 18:20 ET (22:20 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.